Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours ยท Estimated delivery Aug 24 - Aug 29
Research applications require consideration of the peptide's selectivity mechanisms and potential off-target effects, while the well-characterized mechanism provides foundation for power calculations and experimental planning in senescence research applications across diverse biological systems and disease models
R.van der KlinkJ
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
The compound sits within the pineal and AEDG peptide research area, alongside related bioregulator compounds studied for cellular signaling and regulatory function
US$ 25.92
US$ 23.81
US$ 24.59
US$ 25.85
US$ 20.79
